Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

Table 1 Overview of demographics and baseline headache characteristics

	Eptinezumab (N = 238)	Placebo (N = 242)
Age (years), mean (SD)	44.9 (12.0)	44.1 (12.1)
Sex: Female, no. (%)	202 (84.9)	201 (83.1)
Race, no. (%)
White	200 (84.0)	213 (88.0)
Black or African American	30 (12.6)	19 (7.9)
Other^a	8 (3.4)	10 (4.1)
History of chronic migraine, no. (%)^b	25 (10.5)	27 (11.2)
Monthly migraine days, mean (SD)^c	7.2 (2.7)	7.2 (2.6)
Duration of migraine prior to infusion start (hours), mean (SD)^d	3.7 (1.0)	3.7 (1.0)
Severity of headache pain, no. (%)
Moderate	110 (46.2)	117 (48.3)
Severe	128 (53.8)	123 (50.8)

SD standard deviation
^aOther includes Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, other, and multiple
^bMigraine history was collected at the screening visit by the investigator through medical records; if medical records could not be obtained, history was confirmed via patient interview in order to obtain sufficient information to confirm all eligibility criteria are met
^cPatients self-reported the average number of monthly migraine days over the 3 months prior to screening
^dDuration was calculated as the difference between the study drug infusion start date and time and the day 1 headache start date and time

ISSN: 1129-2377